Pharmaceutical Executive: November 2024 Issue (PDF)

Developments in the world of artificial intelligence continue to accelerate at a rapid pace. Our November issue of Pharmaceutical Executive explores a few of those that are starting to deliver measurable gains for the industry.

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

Kebillidi is the first gene therapy to gain FDA approval for the treatment of aromatic L-amino acid decarboxylase deficiency.

In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.

The latest news for pharma industry insiders.

The Jazz Pharmaceutical COO discusses her approach to the role and how it plays into the company’s overall goals.